Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

0.6680 -0.1320 (-16.50%)
Streaming Delayed Price Updated: 10:44 AM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer ↗
On Sunday, The Guardian issued an article that spoke of a UK study that could transform how cancer is treated. The large-scale clinical project assessed how personalized cancer therapies could... 
Via Benzinga
News headline image
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
GANZIMMUN Diagnostics to Feature ColoAlert at the 57th Medizinische Woche Baden-Baden 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Former Senior Advisor To Obama Joins Forces With Innovative Biotech To Catch Cancer Early
Former Senior Advisor To Obama Joins Forces With Innovative Biotech To Catch Cancer Early 
Via News Direct
News headline image
The Covid Era Tech Promises To Reinvent Cancer Treatment ↗
Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning to oncology for its next growth story. 
Via Benzinga
News headline image
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
From Mainz BioMed NV
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Pfizer Advances On Its Cancer Journey ↗
On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024... 
Via Benzinga
News headline image
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early Detection 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool
Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool 
Via News Direct
Topics Artificial Intelligence
News headline image
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
PancAlert is a Next-Generation Pancreatic Cancer Detection Test in Mainz Biomed’s Research and Development Pipeline – Promising Results of First Analysis 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Early Cancer Detection Saves Lives - This Biotech Has A Promising New Test
Early Cancer Detection Saves Lives - This Biotech Has A Promising New Test 
Via News Direct
News headline image
Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones
Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones 
Via News Direct
News headline image
Mainz Biomed's (NASDAQ: MYNZ) Cutting-Edge Colorectal Cancer Test Applies For FDA Breakthrough Status
Mainz Biomed's (NASDAQ: MYNZ) Cutting-Edge Colorectal Cancer Test Applies For FDA Breakthrough Status 
Via News Direct
Topics Artificial Intelligence
News headline image
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer ↗
The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSE: PFE)... 
Via Benzinga
News headline image
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good ↗
This week, Pfizer Inc (NYSE: PFE) revealed a new collaboration to unlock new therapeutic approaches. Its smaller European industry peer specialized in early detection of cancer, Mainz Biomed N.V. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning! 
Via InvestorPlace
News headline image
Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment ↗
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens... 
Via Benzinga
News headline image
Mainz Biomed Provides Half Year 2024 Corporate Update
Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight ↗
On Tuesday, Merck Group revealed an unexpected decision to end a Phase III trial of its cancer drug Xevinapant. This move threatens to undermine confidence the research abilities of the Darmstadt,... 
Via Benzinga
News headline image
Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks
Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks 
Via News Direct
News headline image
Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate
Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate 
Via News Direct
News headline image
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon ↗
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial.  On Monday, Moderna (NASDAQ: MRNA) and Merck & Co... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Reports Results of 2024 Annual General Meeting
From Mainz BioMed NV
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.